XTAE
MRHL
Market cap10mUSD
Jul 08, Last price
154.90ILS
1D
-3.19%
1Q
-16.18%
Jan 2017
7.57%
Name
Merchavia Holdings and Investments Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Merchavia Holdings and Investments Ltd., founded in 1972 and based in Bnei Brak, Israel, operates as an investment company with a primary focus on the Israeli life sciences industry. Its varied portfolio includes funding and developing numerous cutting-edge medical and healthcare solutions. The company's ventures cover: Innovative diagnostic tools aimed at detecting cancer. Wearable medical equipment, such as smartwatches, bracelets, and patches, equipped with sensor technology for health monitoring and diagnostic purposes. Aura smart air, an intelligent, data-driven system that uses user behavior algorithms and real-time smart sensors to oversee and manage both indoor and outdoor air quality. TrainPain, a digital therapeutic designed to enhance the mental and emotional health of individuals suffering from neuropathic and fibromyalgia pain. RevDx (Revolutionary Diagnostics), a compact, handheld device enabling immediate complete blood count analyses. A rechargeable electric cannabis inhaler, which connects via Bluetooth to the VEOLI App for managing dosages and capsule supply. An artificial intelligence-driven neuromonitoring instrument intended for use in operating rooms to prevent nerve damage during surgery. Additionally, Merchavia is engaged in the creation, manufacturing, and commercialization of women's health products. Notable offerings include Ballerine, a copper-based, hormone-free intrauterine contraceptive device, and a spherical endometrial ablation device currently undergoing Phase IIa clinical trials for treating abnormal uterine bleeding. The company was formerly known as Nepco Star Ltd. until its name officially changed to Merchavia Holdings and Investments Ltd. in November 2014.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||